Prevalence of non alcoholic fatty liver disease in the non CAD,CAD patients and correlation of C Reactive Protein with non alcoholic fatty liver disease.

Volume : VII, Issue : V, May - 2018

Dr Ajay Kumar Nandmer, Dr Vijay Kumar Nandmer

Coronary artery atherosclerosis begins at young ages and typically becomes symptomatic after middle–aged with various clinical

(50,51). signs including acute coronary syndrome (ACS) Previous studies have revealed a close relationship between obesity and

(51–54). coronary artery disease (CAD) risk factors Non–alcoholic fatty liver disease (NAFLD) is a clinical and pathological condition

associated with abdominal obesity, Type 2 diabetes mellitus (DM), hypertension and dyslipidemia. Also, NAFLD affects as high as

(55–57). 1423% of the general population, and its prevalence reaches 7090% in obese and type 2 DM patients However, the

associations shown until now include associations among NAFLD and CAD risk factors and subclinical atherosclerosis markers

(56, 58) (58). such as endothelial dysfunction and increased carotid intima–media thickness , and NAFLD and CAD

Patients with NAFLD were associated with more prevalent CAD independent of other risk factors, including glycemic control and

(Met S components 61,62). This finding was despite factoring in the other risk factors for CAD and the components of metabolic

(63) syndrome . In patients with NAFLD, metabolic abnormalities are commonly found and vary from 33 to 100% depending on

(57,61,64) types of study and the selection criteria of NAFLD patients . Central obesity, high triglyceride levels and hypertension are the

major abnormal metabolic syndrome criteria in patients with NAFLD. Metabolic syndrome (MetS) components including central

obesity, hypertension, hypertriglyceridemia, decreased high density lipoprotein cholesterol (HDL–C) and impaired glucose test or

(65) type2 diabetes mellitus (DM) are commonly found in NAFLD . MetS is defined by the presence of three or more of these

metabolic abnormalities by the 2001 National Cholesterol Education Program Adult Treatment Panel III (NCEP–ATPIII) criteria

(66) (67,68). and was modified by the International Diabetes Federation in 2005 as shown inTable2 The criteria of MetS by the

(68) International Diabetes Federation in 2005 considers mandatory the presence of abdominal obesity as measured by waist

(67). circumference(WC) with ethnicity specific, plus any two of other criteria, which is different from those in the ATPIII definition

Non–alcoholic fatty liver disease (NAFLD) affects upto a third of the population worldwide and may confer increased

cardiometabolic risk with consequent adverse cardiovascular outcomes independent of traditional cardiovascular risk factors and

the metabolic syndromes. It is characterized almost universally by insulin resistance and is strongly associated with type 2 diabetes

and obesity. Non alcoholic fatty liver disease is a marker of pathological ectopic fat accumulation combined with a low grade

chronic inflammatory state. This results in several deleterious pathophysiological processes including in abnormal glucose, fatty

acid and lipoprotein metabolism, increased oxidative stress, deranged adipokine profile, hypercoaguability endothelial

dysfunction and accelerated progression of atherosclerosis. This ultimately leads to a dysfunctional cardiometabolic phenotype

with cardiovascular mortality representing the main mode of premature death in NAFLD.

So, in this study we are trying to find out the prevalence of non alcoholic fatty liver disease in CAD patients and correlation of C

reactive protein with NAFLD group of CAD population and Control population.